New mRNA vaccine aims to shield older adults from RSV
NCT ID NCT06564194
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an experimental mRNA vaccine called JCXH-108 to see if it is safe and triggers an immune response against RSV, a common respiratory virus. About 75 healthy volunteers, split into two age groups (18-45 and 60+), will receive either the vaccine or a placebo. Researchers will monitor side effects and measure antibody levels over six months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTIOUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
DelRicht - New Orleans
New Orleans, Louisiana, 70115, United States
-
Health Awareness
Jupiter, Florida, 33458, United States
-
Sundance Clinical Research
St Louis, Missouri, 63131, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One shot, two viruses? new mRNA vaccine targets RSV and hMPV
- Leftover blood samples could unlock new medical discoveries
- La reunion health survey aims to uncover hidden disease patterns
- New mRNA vaccine aims to shield against RSV
- Hunting the genes that make severe infections worse
- Aging immune system under the microscope: study seeks clues to infection risk in seniors